Christina Lake Cannabis to enter South African market

Christina Lake Cannabis has signed a Supply Agreement with MG BioTech Ventures (Pty) Limited, The Africann Group (“Africann”) www.africann.net, to supply custom formulations of medicinal cannabis oils into the South African medical cannabis market.

“Today marks a significant milestone in our revenue growth and product diversification strategy,” said Mark Aiken, Chief Executive Officer of Christina Lake Cannabis. “As we have been focusing on strategic diversification opportunities for our high-quality cannabis products, we are pleased to announce this partnership with one of South Africa’s leading medical cannabis companies. Our goal is to combine our leading-edge technology with our expertise in formulation and cannabinoid customization to create new value-added products for our customers. We believe that as the industry matures, we have a unique opportunity to provide turnkey product solutions that will allow our customers to optimize their business by leveraging our high-quality cannabis products.”

“We are extremely excited about our exclusive supply agreement with Christina Lake Cannabis,” Craig Ludwig, CCO of AfriCann, said. “By accessing their best-of-breed technologies and formulations and as a result of their extremely economical production methodology, AfriCann will be able to provide South African patients with world-leading products at extremely cost-effective price points.”

AfriCann is the first company to introduce legal access to life-changing cannabis medicines to South African patients on a national basis. Utilizing existing medical regulations, the AfriCann group has built a scalable ecosystem to manage every aspect of the medical cannabis journey from patient education, doctor training & consultation, prescription & titration, and distribution of trusted pharma-grade brands in multiple formats to at-home delivery countrywide. They have built an integrated cannabis ecosystem managing the entire doctor and patient journey.